The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy

This parallel assignment, single-blind clinical trial (n=396), aims to evaluate the effectiveness and safety of esketamine injection in modified electroconvulsive therapy (MECT) for depressive patients.

The study, led by the First Affiliated Hospital of Chongqing Medical University, is designed as a multicenter, randomized, controlled trial involving patients receiving MECT for the first time. The research drug, esketamine injection, will be administered at a dose of 17.5mg/70kg in the experimental group, while the control group will receive a saline injection at a dose of 3.5ml/70kg.

The primary outcome measure is the relief rate of depressive symptoms after MECT treatment, defined as two consecutive HDRS-24 scores ≤ 10 points. Secondary outcome measures include HDRS-24 scores after each MECT session, treatment response rate, severe suicidal tendency elimination rate, treatment re-ignition rate, treatment recurrence rate, and changes in cognitive function assessed by the Montreal Cognitive Scale (MoCA).

The study is expected to enrol 396 participants aged 16 to 45 years, with estimated completion in December 2022.

Topic Depression
Compound Ketamine
Country China
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

First Affiliated Hospital of Chongqing Medical University
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.